

WDN/DC:dm 03/04/05 6235-69895-01 360608

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ryuichi Morishita & Munehisa Shimamura

Application No. 10/517,154

Filed: December 6, 2004

Confirmation No. 2664

For: AGENTS FOR GENE THERAPY OF
CEREBROVASCULAR DISORDERS

Examiner: Not yet assigned

Art Unit: 1642

Attorney Reference No. 6235-69895-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney
for Applicant(s)

Date Mailed March 4, 2005

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language and non-English-language documents. The relevance of the non-English-language documents that are enclosed is described in the English-language translation attached to each document. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of the references listed on the accompanying PTO-1449 that were cited in an International Search Report for corresponding International Application No. PCT/JP03/07004 are not enclosed because copies should have been provided directly to the USPTO by WIPO under an exchange program between the USPTO and the Japanese Patent Office. However, Applicants will provide copies of such references upon request.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a


fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


David Cash, Ph.D.
Registration No. 52,706

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number		6235-69895-01	
		Application Number		10/517,154	
		Filing Date		December 6, 2004	
		First Named Inventor		Morishita	
		Art Unit		1642	
		Examiner Name		Not yet assigned	
U.S. PATENT DOCUMENTS Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.					
Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee	
FOREIGN PATENT DOCUMENTS					
Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		Europe	1132098 A1	09/12/2001	MedGene Bioscience, Inc.
		Europe	722737 A1	07/24/1996	Sumitomo Pharmaceuticals Co.
		Europe	1170363 A1	01/09/2002	Kaneda, Yasufumi
		WIPO	WO 01/26694 A1 (w/English Translation)	04/19/2001	MedGene Bioscience, Inc.
		WIPO	WO 01/32220 A1 (w/English Translation)	05/10/2001	MedGene Bioscience, Inc.
		WIPO	WO 02/089854 A1 (w/English Translation)	11/14/2002	Anges Mg, Inc.
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS			
		Hayashi et al., "Gene Therapy for Preventing Neuronal Death Using Hepatocyte Growth Factor: <i>In Vivo</i> Gene Transfer of HGF to Subarachnoid Space Prevents Delayed Neuronal Death in Gerbil Hippocampal CA1 Neurons," <i>Gene Ther.</i> 8:1167-1173 (2001).			
		Ishida et al., "Nokosoku (Nokyoketsu) ni Taisuru Idenshi Chiryo, Noshinkei," 2002 March, Vol. 54, No. 3, pages 213 to 219.			

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	